I
ImmPACT-Bio
Developing novel cell therapies for treating cancer
About ImmPACT-Bio
ImmPACT Bio is a biotechnology startup that is pioneering the development of next-generation cell therapies to address unmet medical needs. The company operates in the healthcare market, specifically focusing on cancer treatment and autoimmune diseases.
The company's business model revolves around the development and commercialization of its proprietary ImmPACT Bio Platforms. These platforms utilize two key technologies: TGF-β CAR and iCAR. TGF-β CAR technology modifies T cell responses to overcome the immune suppressive environment often found in cancer, enabling more effective treatment. iCAR technology, on the other hand, allows for the specific targeting and killing of cancer cells while sparing healthy tissue. This technology has the potential to treat all solid tumors, offering a broad market opportunity.
ImmPACT Bio serves a diverse client base, primarily comprising patients with cancer and autoimmune diseases who have not found effective treatment through existing therapies. The company generates revenue through the development and sale of its innovative cell therapies.
In 2021, ImmPACT Bio merged with Kalthera Therapeutics, a move that likely expanded its research capabilities and market reach. The company prides itself on its team of pioneering scientists and its technologies designed to prevent antigen escape, overcome the immunosuppressive tumor environment, and cure autoimmune diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Los Angeles, United States
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 27.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2024 | $94M | $94M | Lyell Immunopharma | ↗ |
| GRANTOther financing | Feb 2024 | $8M | — | California Institute for Regenerative Medicine | ↗ |
Growth signals
Latest recorded traffic for ImmPACT-Bio is 20 monthly website visits, down 98.6% over the last three months. ImmPACT-Bio's team declined 30% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A12 investors entered at this stage
Takeda Ventures
RM Global - RMG
Novartis Venture Fund
Bukwang Pharmaceutical Co- JPJVC Investment Partners
OrbiMed
Johnson & Johnson Innovation
Foresite Capital
Citadel
Decheng Capital
venBio Partners
Surveyor Capital
Other known investors1 additional known investor
Lyell Immunopharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ImmPACT-Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmPACT-Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.